Specifically, patients with CRLF2 or JAK2/EPOR rearrangements showed a trend toward lower 5-year event-free and overall survival compared to patients with ABL-class alterations or other JAK-STAT pathway alterations [ 9 ].
← all excerpts
The Evolving Role of Hematopoietic Stem Cell Transplantation in Philadelphia-like Acute Lymphoblastic Leukemia: From High-Risk Standard to Precision Strategies.
1
—
—